Further Extension of Maturity Date of June 2017 Note and Financing Update
BOSTON and SYDNEY — 1 July 2020 — GI Dynamics® Inc. (ASX:GID) (”the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date of the...Stockholders Approve Delisting from the Official List
BOSTON and SYDNEY — 22 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020...Placement of $750,000 Unsecured Convertible Promissory Note & Update on Potential Financing and Special Meeting
BOSTON and SYDNEY — 19 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has issued a US$750,000 Unsecured...Further Extension of Maturity Date of June 2017 Note & Fundraising Update
BOSTON and SYDNEY — 17 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date...Videos
How EndoBarrier Works
EndoBarrier: Non-surgical Treatment for Patients with Type 2 Diabetes and …
Maintenance of Efficacy after EndoBarrier
UK First NHS EndoBarrier Service – Dr. Bob Ryder June …
BBC News Item
EndoBarrier treatment for diabetes & obesity following 1 year results …
